Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

ABSTRACT: The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3-1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without re

SUBMITTER: Prasanna PG 

PROVIDER: S-EPMC8009137 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature